DEF 14A

Company

Prelude Therapeutics Inc

Filed

April 29, 2025

Period of Report

June 12, 2025

Accession Number

0000950170-25-059549

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →